title: Amyloid beta peptide causes chronic glial cell activation and neuro-degeneration after intravitreal injection.
abstract: We have previously demonstrated that amyloid beta (Abeta) peptide is acutely toxic to retinal neurones in vivo and that this toxicity is mediated by an indirect mechanism. We have now extended these studies to look at the chronic effect of intravitreal injection of Abeta peptides on retinal ganglion cells (RGC), the projection neurones of the retina and the glial cell response. 5 months after injection of Abeta1-42 or Abeta42-1 there was no significant reduction in RGC densities but there was a significant reduction in the retinal surface area after both peptides. Phosphate-buffered saline (PBS) injection had no effect on retinal size or RGC density. There was a pronounced reduction in the number of large RGCs with a concomitant significant increase in medium and small RGCs. There was no change in cell sizes 5 months after injection with PBS. At 5 months after injection of both peptides, there was marked activation of Muller glial cells and microglia. There was also expression of the major histocompatibility complex (MHC) class II molecule on some of the microglial cells but we saw no evidence of T-cell infiltration into the injected retinas. In order to elucidate potential toxic mechanisms, we have looked at levels of glutamine synthetase and nitric oxide synthase. As early as 2 days after injection we noted that activation of Muller glia was associated with a decrease in glutamine synthetase immuno-reactivity but there was no detectable expression of inducible nitric oxide synthase in any retinal cells. These results suggest that chronic activation of glial cells induced by Abeta peptides may result in chronic atrophy of projection neurones in the rat retina.
authors.affiliation: Department of Cellular and Molecular Neuroscience, Division of Neuroscience & Psychological Medicine, Faculty of Medicine, Imperial College, London, UK. d.walsh@imperial.ac.uk
authors.forename: D T
authors.initials: DT
authors.lastname: Walsh
authors.forename: L
authors.initials: L
authors.lastname: Bresciani
authors.forename: D
authors.initials: D
authors.lastname: Saunders
authors.forename: M F
authors.initials: MF
authors.lastname: Manca
authors.forename: A
authors.initials: A
authors.lastname: Jen
authors.forename: S M
authors.initials: SM
authors.lastname: Gentleman
authors.forename: L S
authors.initials: LS
authors.lastname: Jen
mesh_terms: D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D048429:Cell Size; D005260:Female; D005974:Glutamate-Ammonia Ligase / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D008845:Microinjections; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000473:pathology; D009457:Neuroglia / Q000187:drug effects*; D019001:Nitric Oxide Synthase / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012165:Retinal Ganglion Cells / Q000187:drug effects* / Q000473:pathology*
chemical_list: D016229:Amyloid beta-Peptides; D019001:Nitric Oxide Synthase; D005974:Glutamate-Ammonia Ligase